ライフサイエンスコーパス: L-deprenyl

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 the monoamine oxidase inhibitor selegiline (L-deprenyl).

2 2 is a better index of MAO activity than 11C-L-deprenyl.

3 ly larger for 11C-L-deprenyl-D2 than for 11C-L-deprenyl.

4 A low dose of L-deprenyl (0.01 mg/kg, i.p. every other day for 3 weeks

5 The PET tracer (11)C-deuterium-L-deprenyl ((11)C-DED) has been used to visualize activa

6 , and healthy controls using (11)C-deuterium-L-deprenyl ((11)C-DED) to measure monoamine oxidase B lo

7 11C-L-deprenyl and deuterium-substituted 11C-L-deprenyl (11C-L-deprenyl-D2).

8 not confirm previous findings that low dose L-deprenyl administration in vivo after MPTP can rescue

9 e that obtained with either GM1 or high dose L-deprenyl alone.

10 nd the monoamine oxidase B (MAO-B) inhibitor L-deprenyl, alone and in combination, on striatal dopami

11 radiolabel a novel bis-deuterium substituted l-deprenyl analog (fluorodeprenyl-D2) with (18)F and to

12 studies of the torso area 2 h apart with 11C-L-deprenyl and deuterium-substituted 11C-L-deprenyl (11C

13 Co-administration of GM1 and high dose L-deprenyl caused a synergistic increase in striatal DA

14 Addition of the monoamine (MAO) inhibitors, l-deprenyl, clorgyline, pargyline, or in vivo nialamide

15 Short-term incubation of l-deprenyl combined with DAT and NET uptake inhibitors i

16 A sensitivity analysis showed that 11C-L-deprenyl-D2 is a better index of MAO activity than 11C

17 ut function was significantly larger for 11C-L-deprenyl-D2 than for 11C-L-deprenyl.

18 This study indicates that 11C-L-deprenyl-D2 will be useful for measuring the effects o

19 nd deuterium-substituted 11C-L-deprenyl (11C-L-deprenyl-D2).

20 evels of MAO B is improved by the use of 11C-L-deprenyl-D2, similar to prior studies on the brain.

21 Pittsburgh compound-B (PIB), (11)C-deuterium-L-deprenyl (DED) and (18)F-fluorodeoxyglucose (FDG) resp

22 ly, monoamine oxidase blockers pargyline and l-deprenyl had no effect on DAcyt levels in MPP(+)-treat

23 A high dose of L-deprenyl, inhibiting MAO-B activity, (10 mg/kg, i.p. e

24 Selegiline (L-deprenyl) is a selective, irreversible inhibitor of mo

25 anti-parkinsonian medications which include L-deprenyl, it will be important to further investigate

26 Combined effects of uptake inhibitors with l-deprenyl on dopamine clearance were additive (up to 99

27 Co-administration of GM1 and low dose L-deprenyl was not only not synergistic, but caused GM1s

28 Administration of a 1 mg/kg dose of l-deprenyl yielded 70% inhibition of MAO-B in all region

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。